Biosimilars & Biologics Reports
Showing 1–12 of 22 results
The recent FDA draft-guidance serves as yet another clear indication that biosimilars are becoming a major factor in the healthcare industry. As your organization develops and executes your biosimilar strategy, understanding various stakeholders’ needs, biases, and perceptions will be a strategic advantage.
Call us at +1 (919) 301-0106 for more information on our Biosimilars & Biologics Reports, or email us at sales@isrreports.com.
-
Commercial Bioprocessing Market Outlook
$4,710.00 – $9,420.00 -
Bioprocessing Market Outlook (3rd Ed.)
$4,460.00 – $8,920.00 -
Bioprocessing Market Outlook (2nd Ed.)
$4,460.00 – $8,920.00 -
Biosimilars Manufacturing Outsourcing Models (4th Ed.)
$1,460.00 – $2,920.00 -
Development vs Commercial Outsourced Manufacturing Practices: Biologics
$4,960.00 – $9,920.00 -
Biologic API Contract Manufacturer Quality Benchmarking (2nd edition)
$5,400.00 – $10,800.00 -
Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics
$4,960.00 – $9,920.00 -
Biosimilars in the US Oncology Market (2nd Edition)
$960.00 – $1,920.00 -
Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (3rd Edition)
$900.00 – $1,800.00 -
Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021
$4,960.00 – $9,920.00 -
Biologic API Contract Manufacturer Quality Benchmarking (2016)
$4,960.00 – $9,920.00 -
Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (2015)
$750.00 – $1,500.00
